Abeona Therapeutics Inc (NASDAQ:ABEO) Short Interest Up 17.1% in March

Abeona Therapeutics Inc (NASDAQ:ABEO - Get Free Report) was the target of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 1,990,000 shares, an increase of 17.1% from the March 15th total of 1,700,000 shares. Based on an average trading volume of 333,800 shares, the short-interest ratio is currently 6.0 days. Approximately 7.7% of the shares of the company are short sold.

Abeona Therapeutics Stock Performance

Shares of NASDAQ ABEO traded down $0.24 during midday trading on Friday, reaching $7.55. 188,039 shares of the company traded hands, compared to its average volume of 302,436. The firm has a market cap of $206.49 million, a PE ratio of -2.93 and a beta of 1.49. The stock's 50-day simple moving average is $7.20 and its 200-day simple moving average is $5.50. Abeona Therapeutics has a 12 month low of $2.73 and a 12 month high of $9.01.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last issued its quarterly earnings data on Monday, March 18th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.13). On average, equities research analysts expect that Abeona Therapeutics will post -1.83 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, StockNews.com downgraded shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday, February 19th.

Insider Transactions at Abeona Therapeutics

In other Abeona Therapeutics news, Director Mark Alvino sold 7,084 shares of Abeona Therapeutics stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $5.11, for a total transaction of $36,199.24. Following the sale, the director now owns 62,816 shares in the company, valued at $320,989.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 5.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ABEO. Adage Capital Partners GP L.L.C. raised its holdings in shares of Abeona Therapeutics by 84.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 3,249,994 shares of the biopharmaceutical company's stock valued at $13,682,000 after buying an additional 1,488,834 shares during the last quarter. Point72 Asset Management L.P. bought a new position in shares of Abeona Therapeutics in the fourth quarter valued at about $3,544,000. Armistice Capital LLC bought a new position in shares of Abeona Therapeutics in the fourth quarter valued at about $3,406,000. AIGH Capital Management LLC raised its holdings in shares of Abeona Therapeutics by 77.7% in the third quarter. AIGH Capital Management LLC now owns 1,135,252 shares of the biopharmaceutical company's stock valued at $4,779,000 after buying an additional 496,278 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Abeona Therapeutics by 46.2% in the fourth quarter. Vanguard Group Inc. now owns 1,101,131 shares of the biopharmaceutical company's stock valued at $5,517,000 after buying an additional 348,196 shares during the last quarter. 80.56% of the stock is owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.